Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance

Stock Track10-03

Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.

On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.

However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Kaboom
10-03
Kaboom
Sigh. This company is a joke

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119542827?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-03 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119542827","market":"us","top_or_hot":-1,"title":"Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance","media":"Stock Track","content":"<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.</p>\n\n<p>On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.</p>\n\n<p>However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-03 20:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1119542827","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119542827","pubTimestamp":1727959029,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Novavax Inc.  plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax manage","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"澄清新冠疫苗市场指引后，Novavax股价暴跌9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.\nOn Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.\nHowever, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":356179150815536,"gmtCreate":1727959883556,"gmtModify":1727959887411,"author":{"id":"3573515033218465","authorId":"3573515033218465","name":"Kaboom","avatar":"https://static.tigerbbs.com/5cc3a179bc8939d7ec568911cc826578","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573515033218465","idStr":"3573515033218465"},"htmlText":"Sigh. This company is a joke&nbsp;","listText":"Sigh. This company is a joke&nbsp;","text":"Sigh. This company is a joke","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/356179150815536","repostId":1119542827,"repostType":2,"repost":{"id":"1119542827","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1727959029,"share":"https://ttm.financial/m/news/1119542827?lang=&edition=fundamental","pubTime":"2024-10-03 20:37","market":"us","language":"en","title":"Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1119542827","media":"Stock Track","summary":"Shares of Novavax Inc.  plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax manage","content":"<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.</p>\n\n<p>On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.</p>\n\n<p>However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Shares Tumble 9% After Clarifying COVID Vaccine Market Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-03 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.</p>\n\n<p>On Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.</p>\n\n<p>However, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119542827","content_text":"Shares of Novavax Inc. (NVAX) plunged over 9% in pre-market trading on Thursday after the biotechnology company clarified that it has not reaffirmed or updated its full-year 2024 financial guidance for the U.S. COVID-19 vaccine market, contrary to a recent analyst report.\nOn Wednesday, Novavax's stock soared nearly 19% after Jefferies analyst Roger Song suggested in a research note that the company would likely meet its 2024 revenue guidance. Song's assessment was based on a meeting with Novavax management, where he concluded that trends in this year's COVID-19 vaccine sales would follow a similar pattern as 2023.\nHowever, Novavax swiftly clarified that while it is aware of the analyst report, it has not provided any updates or reaffirmations regarding its full-year 2024 outlook since the Q2 2024 financial results in August. This clarification appeared to trigger a sharp reversal in investor sentiment, resulting in a significant pre-market decline in the company's share price.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119542827"}